

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



首程控股有限公司
SHOUCHENG HOLDINGS LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 697)

**VOLUNTARY ANNOUNCEMENT
REGARDING AN ADDITIONAL INVESTMENT IN TOWARDPI**

This announcement is made by Shoucheng Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company is pleased to announce that recently, the fund managed by a wholly-owned subsidiary of the Company under Shoucheng Capital of the Group, has invested in TowardPi (Beijing) Medical Technology Group Co., Ltd.* (圖湃(北京)醫療科技集團股份有限公司, formerly known as TowardPi (Beijing) Medical Technology Ltd.* (圖湃(北京)醫療科技有限公司), “**TowardPi**”). This investment is an additional investment following the investment made in March 2025, which will further promote the product research, development and iteration upgrading of the invested enterprise, as well as further advance its global commercial expansion.

TowardPi is an innovative enterprise focusing on the research, development and production of high-end ophthalmic medical equipment. With ophthalmic imaging diagnostic and therapeutic equipment as its core, leveraging its self-developed optical imaging, artificial intelligence and precision manufacturing technologies, it is committed to providing intelligent, precise and minimally invasive one-stop ophthalmic clinical solutions for global medical institutions, aspiring to become a full-platform supplier of high-end global ophthalmic equipment. This investment will provide greater momentum for TowardPi in terms of working capital reserves, product iteration and upgrades and global commercial expansion, assisting it in achieving greater breakthroughs in technological research and development and actively supporting its overseas market expansion.

Looking ahead, the Group will continue to increase its investment layout in the robot industry unwaveringly, particularly by maintaining continuous cooperation with leading enterprises in niche sectors. It is committed to promoting the integrated development of medical robotics and its upstream and downstream industrial chains through capital empowerment and industrial synergy, helping to elevate the high-end medical robotics industry ecosystem to new heights.

By order of the Board
Shoucheng Holdings Limited
Zhao Tianyang
Chairman

Hong Kong, 26 March 2026

As at the date of this announcement, the Board comprises Mr. Zhao Tianyang (Chairman), Mr. Li Hao (Vice Chairman), Mr. Xu Huajie and Mr. Liu Jingwei as Executive Directors; Mr. Peng Jihai and Mr. Ho Gilbert Chi Hang as Non-executive Directors; Dr. Wang Xin, Ms. Zhang Quanling, Ms. Zhuge Wenjing, Dr. Zhang Jianwei and Ms. Tse, Theresa Y Y as Independent Non-executive Directors.

** For identification purposes only*